Thursday 1 August 2013

Just Releases Research : Global Construction Aggregates Market - Key Trends and Opportunities to 2017

Synopsis

This report provides detailed market analysis, information, trends, issues and insights 
into the global constructionaggregates market, including:

  • The regional and global construction aggregates market's growth prospects by category
  • Analysis of the Asia-Pacific, Middle East, North America, Latin America and European markets separately with country level data
  • Critical insight into the impact of the market through comparative analysis of country level data
  • Company profiles of key companies operating in the construction aggregates industry



Now Available : China Rare Earth Permanent Magnet Industry Report, 2012-2015

Amid the global economic downturn and the falling prices of upstream rare earth raw materials and NdFeB products, the demand for downstream NdFeB dropped dramatically in 2012. China’s NdFeB apparent consumption will rebound stably in the wake of the recovered demand in consumer electronics, automotive motors and other major downstream industries since 2013.




China Rare Earth Permanent MagnetIndustry Report, 2012-2015 analyzes the global and Chinese rare earth permanent magnet markets as well as forecasts development trends from the angles of rare earth raw material supply, rare earth permanent magnet supply and demand, market prices and major production enterprises.

In H1 2012, the operating rate of China NdFeB industry was less than 50%. High-end NdFeB manufacturers maintained the operating rate as high as 70%-75%, while low-end NdFeB companies only saw 30%-40%. Since 2013, downstream industries have transferred from “de-stocking” to “re-stocking”, which stimulated the growth in orders for NdFeB and boosted the industrial operating rate obviously. In Q2 2013, the operating rate of major Chinese NdFeB producers returned to 70-80%.

By 2014 when the patent licenses of Japanese Sumitomo and U.S. Magnequench will expire in European, American and Japanese NdFeB markets, Chinese NdFeB enterprises will witness breakthroughs in export, but eight of them who hold export patent licenses (including Zhong Ke San Huan and Ningbo Yunsheng) will also face fierce competition herein.



Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948

Research Report on Global and China Monoclonal Antibody Industry, 2013-2017

Antibody drugs are usually generated from monoclonal antibody through genetic engineering, with the advantages of strong targeting, few side effects, etc. With rather promising application prospect in clinic treatment, antibody drugs are mainly applied in curing diseases like tumour, immune system and so on. In terms of the global market, antibody drugs account for over 40% of the entire biotech drug market and the market share still keeps increasing. Antibody drugs have become one of the most important parts of biotech drugs and monoclonal antibody drugs are even star products of antibody drugs. Among the top 10 best selling drugs in 2012, six of them were monoclonal antibody drugs with each annual sales value exceeding USD 5 billion.




In recent years, the market scale of monoclonal antibody drugs increased rapidly. In 2012, the global sales value of monoclonal antibody preparation exceeded USD 50 billion. Among that, Roche (plus Genentech) was the leading monoclonal antibody enterprises, which possessed seven products sold in the market including Avastin, Herceptin, Rituximab, etc. In 2012, its sales value of monoclonal antibody products reached USD 20 billion. Mono antibody drugs will become the main force promoting the development of biological drugs in the next few years.


To Buy A Copy Of This Report Visit :  http://www.marketresearchreports.biz/analysis/172373


In recent years, China bio pharmaceuticals industry develops rapidly, but antibody drugs lag far behind the average international level with sales value being less than 3% of biological drug share. At present, China antibody drug market is still in the initial stage. However, with Shanghai CITIC National Health Pharmaceutical Co., Ltd. and Biotech Pharmaceutical Co., Ltd. releasing humanization products, product types of domestic antibody drugs will enter the upgrading stage. Although domestic full humanization products have not been released, humanization products and full humanization products will become the domestic trend of monoclonal antibody products in the future.


Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948

Challenges and Opportunities in the Renal Denervation Market


Hypertension: Prevalence and Significance

Hypertension is one of the most preventable causes of premature morbidity and mortality globally. It is a major risk factor for stroke, myocardial infarction, heart failure, chronic kidney disease, peripheral vascular disease, cognitive decline, damage to retinal blood vessels and visual impairment, and premature death. Therefore, reducing hypertension can lower the incidence of these conditions, helping to improve the health of the population and reducing the high burdens that they place on global healthcare systems.




Renal denervation therapy involves a surgical procedure and is therefore a last resort in the treatment of hypertension. It is only considered when cheaper, simpler and potentially safer alternatives such as lifestyle modifications and the use of pharmaceuticals have failed. These patients are termed as having treatment-resistant hypertension.


To Buy A Copy Of This Report Visit :  http://www.marketresearchreports.biz/analysis/172371


Current Trends and Future Opportunities

With renal denervation technology only having been in development since the late 1990s and commercially-available since 2010, the market is in its infancy. The products remain unapproved in the US and Japan, and reimbursement is not yet widely available in other regions. Despite being an emerging market, renal denervation has sparked considerable interest due to the good safety and efficacy results it has achieved so far in helping to reduce treatment-resistant hypertension. The expectation is that renal denervation could become a multi-billion dollar market in the future. However, the success of any new medical technology is dependent on regulatory approval and reimbursement; acceptance and awareness from the medical community; and evidence of safety, efficacy and cost-effectiveness. All of these elements must be in place for the market to realise its potential.

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948

China High Voltage DC Power Supply Market 2013-2017

With the development of power electronics technology and the emergence of new high-performance, high withstanding voltage and high-frequency power electronic devices, high voltage DC power supply is widely applied in industry, agriculture, health care, defense and scientific research, such as: X-ray tube, bone density testing, analytical instruments, electrophoresis, semiconductors, ion implantation, lithography, non-destructive testing, X-ray imaging, electrostatic dust removal, lampblack purification, electrostatic spraying, CT machines, laser equipment, ozone equipment, etc.




At present, technological gap between domestic high voltage power supply products and that in foreign countries still exist; a large quantity of core devices had to rely on imports so as to guarantee the products quality.


To Buy A Copy Of This Report Visit :  http://www.marketresearchreports.biz/analysis/172014


The survey of Huidian Research shows that since 2008, with the widening of the application areas, HVDC power supply showed a rapid growth rate; the average annual growth rate was higher than 60%. Impacted by the macro environment in 2012, the growth speed was slowed down; the sales volume was 160,000 units, up 33% YoY; the sales revenue was CNY 1.8 billion, up 38% YoY. Because the quality of the domestic core devices is relatively poor, a large number of products are imported from foreign counties; the imported products account for about 1/3 of the market share currently. 

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948